Ally Bridge Group NY LLC Sells 18,519 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Ally Bridge Group NY LLC decreased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 90,292 shares of the company's stock after selling 18,519 shares during the period. Janux Therapeutics accounts for about 4.1% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 9th largest position. Ally Bridge Group NY LLC owned about 0.17% of Janux Therapeutics worth $4,834,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JANX. RA Capital Management L.P. lifted its position in shares of Janux Therapeutics by 13.1% in the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. Freestone Grove Partners LP purchased a new position in shares of Janux Therapeutics in the fourth quarter worth $364,000. First Light Asset Management LLC purchased a new stake in Janux Therapeutics in the 4th quarter worth $16,800,000. Northern Trust Corp increased its holdings in shares of Janux Therapeutics by 15.9% in the fourth quarter. Northern Trust Corp now owns 308,800 shares of the company's stock worth $16,533,000 after purchasing an additional 42,302 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Janux Therapeutics by 107.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 63,512 shares of the company's stock worth $3,400,000 after purchasing an additional 32,917 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at $2,464,170. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 10,001 shares of company stock worth $313,964 in the last three months. Corporate insiders own 29.40% of the company's stock.

Janux Therapeutics Stock Up 0.5 %

JANX stock traded up $0.13 during trading on Wednesday, hitting $25.67. The company had a trading volume of 720,999 shares, compared to its average volume of 856,932. The firm has a market capitalization of $1.52 billion, a P/E ratio of -21.91 and a beta of 3.24. The company has a 50 day simple moving average of $29.61 and a 200-day simple moving average of $42.21. Janux Therapeutics, Inc. has a 52-week low of $22.47 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

JANX has been the subject of several research analyst reports. Wedbush restated an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Scotiabank reduced their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.